Age and gender distribution of people presenting with breathlessness as one of the <i>reasons for encounter</i> to general practice in Australia 2000-2009.

<p>Missing data removed from analysis (n=68).</p

Consultation characteristics by breathlessness status at the encounter of people presenting with breathlessness as one of the <i>reasons for encounter</i> to general practice in Australia 2000-2009.

<p>Missing data removed from analysis.</p><p>RACF − residential aged care facility; MBS − Medicare Benefits Schedule; DVA − Department of Veterans’ Affairs.</p><p>(a) MBS/DVA items other than level A, B, C, D items, and workers compensation claim, or other paid (hospital, state etc), and no charge.</p><p>(b) No MBS/DVA items or type of consultation (workers compensation claim, other paid, or no charge) recorded.</p><p>(c) MBS/DVA items and other types of encounter (workers compensation claim, or other paid [hospital, state etc], or no charge) that do not designate the place of consultation.</p><p>(d) Level A <5 minutes (uncomplicated consultation e.g. immunisation); Level B <20 minutes with limited physical examination; Level C long consultations (20-40 minutes); and Level D >40 minutes.</p

Consultation outcome by place of consultation of people presenting with breathlessness as one of the <i>reasons for encounter</i> to general practice in Australia 2000-2009.

<p>Missing data removed from analysis (n= 617; 8.5%); RACF-residential aged care facility.</p><p>^*Includes telephone consultations, indirect encounters and seeing people in other hospitals.</p

Effects of rare kidney diseases on kidney failure: a longitudinal analysis of the UK National Registry of Rare Kidney Diseases (RaDaR) cohort

Individuals with rare kidney diseases account for 5-10% of people with chronic kidney disease, but constitute more than 25% of patients receiving kidney replacement therapy. The National Registry of Rare Kidney Diseases (RaDaR) gathers longitudinal data from patients with these conditions, which we used to study disease progression and outcomes of death and kidney failure.People aged 0-96 years living with 28 types of rare kidney diseases were recruited from 108 UK renal care facilities. The primary outcomes were cumulative incidence of mortality and kidney failure in individuals with rare kidney diseases, which were calculated and compared with that of unselected patients with chronic kidney disease. Cumulative incidence and Kaplan-Meier survival estimates were calculated for the following outcomes: median age at kidney failure; median age at death; time from start of dialysis to death; and time from diagnosis to estimated glomerular filtration rate (eGFR) thresholds, allowing calculation of time from last eGFR of 75 mL/min per 1·73 m2 or more to first eGFR of less than 30 mL/min per 1·73 m2 (the therapeutic trial window).Between Jan 18, 2010, and July 25, 2022, 27 285 participants were recruited to RaDaR. Median follow-up time from diagnosis was 9·6 years (IQR 5·9-16·7). RaDaR participants had significantly higher 5-year cumulative incidence of kidney failure than 2·81 million UK patients with all-cause chronic kidney disease (28% vs 1%; p Background Methods Findings Interpretation Funding</p